Initial Study of Human Genetic Contribution to COVID-19 Severity and Susceptibility - Wang, Fang; Huang, Shujia; Gao, Rongsui; Zhou, Yuwen; Lai, Changxiang; Li, Zhichao; Xian, Wenjie; Qian, Xiaobo; Li, Zhiyu; Huang, Yushan; Tang, Qiyuan; Liu, Panhong; et al. (medRxiv, 2020)
The COVID-19 pandemic has accounted for more than five million infections and hundreds of thousand deaths worldwide in the past six months. The patients demonstrate a great diversity in clinical and laboratory manifestations and disease severity. Nonetheless, little is known about the host genetic contribution to the observed inter-individual phenotypic variability. Here, we report the first host genetic study in China by deeply sequencing and analyzing the 332 COVID-19 patients categorized by varying levels of severity from the Shenzhen Third People’s Hospital. Based on a total of 22.2 million genetic variants, we conducted both single-variant and gene-based association tests among the five severity groups including asymptomatic, mild, moderate, severe and critical ill patients after the correction of potential confounding factors. The most significant gene loci associated with severity is located in TMEM189-UBE2V1 involved in the IL-1 signaling pathway. The p.Val197Met missense variant that affects the stability of the TMPRSS2 protein displays a decreasing allele frequency among the severe patients compared to the mild and the general population. We also identified that the HLA-A*11:01, B*51:01 and C*14:02 alleles significantly predispose the worst outcome of the patients. This initial study of Chinese patients provides a comprehensive view of the genetic difference among the COVID-19 patient groups and highlighted genes and variants that may help guide targeted efforts in containing the outbreak. Limitations and advantages of the study was also reviewed to guide future international efforts on elucidating the genetic architecture of host-pathogen interaction for COVID-19 and other infectious and complex diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by National Natural Science Foundation of China (31900487), Guangdong Provincial Key Laboratory of Genome Read and Write (No. 2017B030301011) and China National GeneBank (CNGB). We would like to acknowledge Fan Zhang from Illumina, Zilong Li and Kang Fang, Defu Xiao from BGI, Xinjun Zhang from University of California, Los Angeles, Emilia Huerta-Sanchez from Brown University and Rasmus Nielsen from University of UC Berkeley for helpful discussions of the results and advice.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics commissions of the Shenzhen Third People’s Hospital Ethics Committee with a waiver of informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study, including the allele frequency for the five groups of patients at all the 20 million detected genetic variants and the genome-wide association test summary statistics have been deposited in CNSA (China National Genebank Sequence Archive)in Shenzhen, China with accession number CNP0001107 (https://db.cngb.org/cnsa/).